Towards a best-in-class IgE disruptor for food allergy with Claude-enabled antibody design

A Claude-guided biparatopic antibody design campaign identified three disruptor variants that removed more receptor-bound IgE than omalizumab at 25–400 nM.

• Why it matters: Food allergy is driven by FcεRI-bound IgE that can persist for weeks, so neutralizing circulating IgE may leave residual receptor-bound IgE capable of sustaining sensitivity.
• What they did: The team used an agentic computational design approach to create a disruptor arm plus a non-competing anchor arm, then tested 91 designs by competitive bio-layer interferometry and dose titration.
• The result: Three variants showed greater IgE removal than omalizumab at therapeutically relevant concentrations (25–400 nM), and anchor-arm designs bound IgE at diverse epitopes with apparent affinities of 3.4–235 nM.

AI summary of the abstract · may contain errors · not medical advice · read the paper.